ClinicalTrials.gg
CompletedNCT04674800Updated Aug 3, 2026Results posted

Extension Study of MYL-1701P-3001 for Safety and Efficacy

A Phase 3 interventional study of MYL-1701P, a proposed biosimilar to Eylea in Diabetic Macular Edema, sponsored by Mylan Pharmaceuticals Inc. Completed at 15 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Macular Edema with a site in India — none open to participants now, 1 under way, none of them phase 3. Macular Edema · India.

Enrollment
22nd of 26
52 · median 197
Started
2020
with 1 other
Phase 3
12 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
2 of 26
Mylan Pharmaceuticals Inc

Among the 26 studies in Macular Edema with a site in India, this one is the 22nd largest by enrollment, is one of 2 that started in 2020, is one of 12 in phase 3, and was the 19th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 26 studies in Macular Edema with a site in India is open now. The open studies under Macular Edema, anywhere →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Macular Edema with a site in India as a file.
02

Study summary

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.

Read the detailed description

Diabetic retinopathy is an important cause of blindness worldwide. The International Diabetes Federation estimates that 285 million people worldwide have diabetes mellitus and approximately 7% of these individuals are affected by diabetic macular edema.

EYLEA® (aflibercept) injection, an anti-Vascular Endothelial Growth Factor (VEGF) agent, has been approved by the FDA and EMA for the treatment of Diabetic Macular Edema (DME).

Mylan Inc. and Momenta Pharmaceuticals, Inc. are developing MYL-1701P, a proposed biosimilar to Eylea.

MYL-1701P-3001 (NCT03610646) study was designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of MYL-1701P in the treatment of subjects with Diabetic Macular Edema (DME). Eligible subjects from MYL-1701P-3001 (NCT03610646) study will be enrolled in the AFIL-IJZ-3002 study. All enrolled subjects will receive three doses of MYL-1701P every eight weeks. Subjects will attend the clinic visits for safety and efficacy assessments including Best Corrected Visual Acuity (BCVA), Spectral domain- Optical Coherence Tomography (SD-OCT), complete ophthalmological examinations during the study.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • BCVA
  • ETDRS Letters
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject participated in the MYL-1701P-3001 study
  2. Subject requires treatment with intravitreal anti-VEGF therapy
  3. Subject is able to understand and voluntarily provide written to participate in the study.
  4. If female of , the subject must have negative pregnancy tests and should not be nursing or planning a pregnancy.
  5. Subject is willing to comply with the study duration, study visits and study related procedures.
  6. If female, subject must be:

    • Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; or
    • Of childbearing potential and practicing an acceptable form of
    • Of non-childbearing potential
  7. If male, subject must be surgically or biologically sterile. If not sterile, the subject must agree to use an acceptable form of birth control

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known to aflibercept or any of the
  2. Subjects will be excluded if any of the following conditions are met in the study eye:

    • Subjects with active ocular inflammation.
    • Subjects with uncontrolled glaucoma
    • Surgery for glaucoma in the past or likely to be needed in the future.
  3. Subjects with active or suspected ocular or periocular infection including but not limited to infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye.
  4. Subjects who plan to participate in another clinical study while enrolled in this study.
  5. Subjects receiving treatment for a serious systemic infection.
  6. Subjects with uncontrolled hypertension defined as systolic blood pressure > 160 mm Hg or diastolic blood pressure > 95 mm Hg.
  7. Subjects with a history of cerebrovascular accident or myocardial infarction within 6 months of enrollment.
  8. Subjects with renal failure requiring dialysis or renal transplant.
  9. Subjects with a history or presence of any condition, that in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Single, test arm

    Open label, single arm study

    Biological: MYL-1701P, a proposed biosimilar to Eylea

Interventions

  • BiologicalMYL-1701P, a proposed biosimilar to Eylea

    MYL-1701P- 3 doses each of 2 mg at 8 weeks interval

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs).

    Incidence of treatment-emergent adverse events was defined as the number and percentage of participants experiencing at least one TEAE during the study period. Incidence is reported as categorical participant counts rather than person-time-based rates due to the fixed study duration.

    Time frame: Week 20

Secondary outcomes

  1. Change From Baseline in BCVA at Week 8

    Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

    Time frame: Week 8

  2. Change From Baseline in CRT at Week 8

    Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

    Time frame: Weeks 8

  3. Change From Baseline in BCVA at Week 16

    Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

    Time frame: Week 16

  4. Change From Baseline in BCVA at Week 20

    Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

    Time frame: Week 20

  5. Change From Baseline in CRT at Week 16

    Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

    Time frame: Week 16

  6. Change From Baseline in CRT at Week 20

    Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

    Time frame: Week 20

07

Results

Posted Aug 3, 2026

Participant flow

Parent study (MYL-1701P-3001) was designed to demonstrate the clinical similarity of MYL 1701P and Eylea regarding efficacy, safety, pharmacokinetics, and immunogenicity in the treatment of subjects with DME. AFIL-IJZ-3002 study was designed and conducted by Mylan to further evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of subjects who successfully completed the parent study MYL-1701P-3001.

Participant flow — Overall Study
MilestoneSingle, Test Arm
Started52
Completed46
Not completed6

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events (TEAEs).

Incidence of treatment-emergent adverse events was defined as the number and percentage of participants experiencing at least one TEAE during the study period. Incidence is reported as categorical participant counts rather than person-time-based rates due to the fixed study duration.

Time frame:
Week 20
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events (TEAEs).
ParticipantsSingle, Test Arm
Incidence of Treatment Emergent Adverse Events (TEAEs).16
SecondaryChange From Baseline in BCVA at Week 8

Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

Time frame:
Week 8
Reported as:
Mean · Letters
Change From Baseline in BCVA at Week 8
LettersSingle, Test Arm
Change From Baseline in BCVA at Week 81.4 ± 2.88
SecondaryChange From Baseline in CRT at Week 8

Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

Time frame:
Weeks 8
Reported as:
Mean · Microns
Change From Baseline in CRT at Week 8
MicronsSingle, Test Arm
Change From Baseline in CRT at Week 8-23.8 ± 102.42
SecondaryChange From Baseline in BCVA at Week 16

Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

Time frame:
Week 16
Reported as:
Mean · Letters
Change From Baseline in BCVA at Week 16
LettersSingle, Test Arm
Change From Baseline in BCVA at Week 161.4 ± 3.74
SecondaryChange From Baseline in BCVA at Week 20

Best Corrected Visual Acuity (BCVA) will be assessed by Early Treatment Diabetic Retinopathy Letters (ETDRS)

Time frame:
Week 20
Reported as:
Mean · Letters
Change From Baseline in BCVA at Week 20
LettersSingle, Test Arm
Change From Baseline in BCVA at Week 201.5 ± 3.80
SecondaryChange From Baseline in CRT at Week 16

Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

Time frame:
Week 16
Reported as:
Mean · Microns
Change From Baseline in CRT at Week 16
MicronsSingle, Test Arm
Change From Baseline in CRT at Week 16-6.2 ± 130.55
SecondaryChange From Baseline in CRT at Week 20

Central retinal thickness (CRT) will be evaluated using spectral-domain-optical coherence tomography (SD-OCT)

Time frame:
Week 20
Reported as:
Mean · Microns
Change From Baseline in CRT at Week 20
MicronsSingle, Test Arm
Change From Baseline in CRT at Week 20-14.8 ± 89.71

Adverse events

Collected over The total study duration was 24 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single, Test Arm0/52 (0%)1/52 (1.9%)16/52 (30.8%)
Most frequent serious events
Most frequent serious events
EventSingle, Test Arm
Cerebral InfarctionNervous system disorders1/52
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSingle, Test Arm
Glycosylated haemoglobin increasedInvestigations4/52
Eye painEye disorders3/52
CataractEye disorders2/52
PyrexiaGeneral disorders2/52
Bundle branch block leftCardiac disorders1/52
Cataract nuclearEye disorders1/52
Diabetic retinal oedemaEye disorders1/52
Eye irritationEye disorders1/52
Ocular hyperaemiaEye disorders1/52
Posterior capsule opacificationEye disorders1/52

Baseline characteristics

All enrolled population

Age, Categorical
Age, Categorical(Participants)Single, Test Arm
<=18 years0
Between 18 and 65 years41
>=65 years11
Sex: Female, Male
Sex: Female, Male(Participants)Single, Test Arm
Female16
Male36
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single, Test Arm
Hispanic or Latino0
Not Hispanic or Latino52
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single, Test Arm
American Indian or Alaska Native0
Asian52
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Single, Test Arm
India52
Best Corrected Visual Acuity
Best Corrected Visual Acuity(Letters)Single, Test Arm
Mean70.6 ± 14.1
Corneal Retinal Thickness
Corneal Retinal Thickness(micrometers)Single, Test Arm
Mean318.7 ± 132.85
08

Study locations

15 sites
  • Mylan Investigative site
    Hyderabad, Andhra Pradesh 500034, India
  • Mylan Investigative Site
    Visakhapatnam, Andhra Pradesh 530 040, India
  • Mylan Investigative Site
    Ahmedabad, Gujarat 380015, India
  • Mylan Investigative site
    Ahmedabad, Gujarat 380016, India
  • Mylan Investigative site
    Bangalore, Karnataka 560 010, India
  • Mylan Investigative Site
    Bangalore, Karnataka 560094, India
  • Mylan Investigative Site
    Bengaluru, Karnataka 560037, India
  • Mylan Investigative Site
    Mumbai, Maharashtra 400050, India
  • Mylan Investigative site
    New Delhi, New Delhi 110029, India
  • Mylan Investigative site
    Bhubaneswar, Odisha 751024, India
  • Mylan Investigative Site
    Chandigarh, Punjab 160012, India
  • Mylan Investigative site
    Jaipur, Rajasthan 302015, India
  • Mylan Investigative site
    Madurai, Tamil Nadu 625 020, India
  • Mylan Investigative site
    Tirunelveli, Tamil Nadu 627002, India
  • Mylan Investigative Site
    Noida, Uttar Pradesh 201301, India
09

References and documents

Publications

  • Chauhan R, Gupta V, Natesh S, Vohra R, Agarwal V, Ganapathi PC, Bose D, Loganathan S. Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. BMJ Open Ophthalmol. 2026 Jun 29;11(2):e002637. doi: 10.1136/bmjophth-2025-002637. PubMed 42373197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2022, 16 months.

Results were first posted in Aug 2026, 4 years 3 months after primary completion. A results delay was requested in Aug 2022.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 19, 2020
StartActual
Nov 23, 2020
Primary completionActual
Apr 20, 2022
CompletionActual
Apr 20, 2022
Results delay requested
Aug 25, 2022
Results first posted
Aug 3, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04674800
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Nov 23, 2020
Primary completion
Apr 20, 2022
Completion
Apr 20, 2022
Results posted
Aug 3, 2026
Last update
Aug 3, 2026

Study contacts

Prasanna Ganapathi, MD
study director · Mylan Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion